<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065087</url>
  </required_header>
  <id_info>
    <org_study_id>GX-I7-CA-007</org_study_id>
    <nct_id>NCT04065087</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma</brief_title>
  <official_title>A Phase 1/2, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability, Anti-tumor Activity of GX-I7 Plus Adjuvant Temozolomide Combination Regimen in Patients With Newly Diagnosed With Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2, randomized, placebo-controlled study to evaluate safety, tolerability,
      anti-tumor activity and impact on absolute lymphocyte count of GX-I7 plus adjuvant
      temozolomide combination regimen in patients with newly diagnosed with glioblastoma who
      completed standard concurrent chemo-radiation therapy (CCRT)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In dose escalation stage (Phase 1 part), low/intermediate/high dose of GX-I7 will be
      administered in combination with adjuvant temozolomide to find recommended phase 2 dose.

      Phase 2 part will be randomized, placebo controlled study and GX-I7 or Placebo will be
      administered in combination with adjuvant temozolomide treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 22, 2019</start_date>
  <completion_date type="Anticipated">August 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 1: sequential dose escalation Phase 2: randomized, placebo controlled, parallel arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>lymphocyte count</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in absolute lymphocyte count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>Median overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Median progression free survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Newly Diagnosed Glioblastoma</condition>
  <arm_group>
    <arm_group_label>GX-I7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-I7 administered until Progression of Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered until Progression of Disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GX-I7</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>GX-I7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form (ICF)

          2. Age ≥ 19 years

          3. Gross total resection equal to or greater than 80% based on post-op MRI, compared to
             pre-op MRI (Patients requiring biopsy only is not eligible)

          4. Patients newly diagnosed with glioblastoma either by imaging or pathology testing,
             requiring concurrent chemo-radiotherapy (CCRT) and adjuvant temozolomide chemotherapy
             with curative intent

          5. Karnofsky score ≥ 60

          6. Life expectancy &gt; 12 weeks

        Exclusion Criteria:

          1. Gliomatosis cerebri

          2. Isocitrate dehydrogenase 1 &amp; 2 mutation

          3. Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yun Jung Choi, Ph.D</last_name>
    <phone>82 31 628 3210</phone>
    <email>yunjung.choi@genexine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misun Byun, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

